RXi Closes Acquisition of Apthera | GenomeWeb

RXi Pharmaceuticals said this week that it has closed its acquisition of peptide immunotherapy firm Apthera.

As previously announced, RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one (GSN 3/31/2011). Among Apthera's assets is the phase II breast cancer treatment NeuVax.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.